Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€129.92

€129.92

-0.700%
-0.92
-0.700%
€169.36
 
26.06.25 / Tradegate WKN: 853260 / Symbol: JNJ / Name: Johnson & Johnson / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

Description Johnson & Johnson

Johnson Johnson is a multinational corporation that specializes in medical devices, pharmaceuticals, and consumer packaged goods. The company was founded in 1886 and is headquartered in New Brunswick, New Jersey.

Johnson Johnson products can be found in over 175 countries around the world, and the company has more than 250 operating companies that employ over 130,000 people globally.

The company's pharmaceuticals segment develops and markets prescription drugs, including oncology, immunology, and infectious disease treatments. Its medical devices segment produces products such as surgical instruments and diagnostic equipment. Its consumer segment produces a variety of household products, including baby care, skin care, and oral care products.

As of September 2021, the company has a market capitalization of over $445 billion and is listed on the New York Stock Exchange under the symbol "JNJ".

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Johnson & Johnson is only available for our menbers.
Not a member yet? Sign up for free!

Competitors of Johnson & Johnson

Johnson Johnson (JNJ) is a global healthcare company that operates in various segments, including consumer health, pharmaceuticals, and medical devices. Some of its significant competitors in each segment are:

1. Consumer Health:
- Procter Gamble (PG) - Competes with JNJ's OTC products such as Tylenol, Motrin, Listerine, and Benadryl
- Bayer AG (BAYRY) - Competes with JNJ's OTC products such as Band-Aid, Neosporin, and Sudafed

2. Pharmaceuticals:
- Pfizer Inc. (PFE) - Competes with JNJ's pharmaceuticals such as Remicade, Zytiga, and Stelara
- Merck Co., Inc. (MRK) - Competes with JNJ's pharmaceuticals such as Procrit, Simponi, and Zytiga

3. Medical Devices:
- Medtronic Plc. (MDT) - Competes with JNJ's medical devices such as DePuy Synthes, Ethicon, and Cordis
- Boston Scientific Corporation (BSX) - Competes with JNJ's medical devices such as Biosense Webster, Cerenovus, and Mentor

It is important to note that JNJ has a diversified business model, and its competitors may vary by segment and product category.

Suppliers of Johnson & Johnson

As a healthcare company, Johnson Johnson has a wide range of suppliers that provide various raw materials, components, and services to support its operations. Some of the most important suppliers for Johnson Johnson include:

1. Pharmaceutical suppliers – These suppliers provide the raw materials to manufacture pharmaceuticals and over-the-counter drugs, including active pharmaceutical ingredients (APIs), excipients, and other materials.

2. Medical device suppliers – These suppliers provide components and raw materials for medical devices and equipment, including implantable devices, surgical instruments, and diagnostic tests.

3. Packaging suppliers – These suppliers provide the materials and packaging technologies for Johnson Johnson's products, including bottles, tubes, and blister packs.

4. Logistics and distribution suppliers – These suppliers provide transportation, warehousing, and distribution services to ensure that Johnson Johnson's products are delivered to their customers efficiently and effectively.

5. Research and development suppliers – These suppliers provide laboratory equipment, research services, and other support for Johnson Johnson's R efforts to develop new products and treatments.

In summary, Johnson Johnson's important suppliers are a crucial part of its operations, providing the necessary materials and services to produce high-quality healthcare products with maximum efficiency.

Financial data and news for Johnson & Johnson

sharewise wants to provide you with the best news and tools for Johnson & Johnson, so we directly link to the best financial data sources.

News

Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions
Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions

Johnson & Johnson is generating significant attention in both medical and financial circles following impressive study results for its multiple myelom treatments. The pharmaceutical giant's cancer

Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback

Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The

Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson Stock: Court Setback Triggers Financial Shift

Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately

Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth

Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous

Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges
Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges

Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears

Johnson & Johnson Stock: Resilient Performance Amid Market Volatility
Johnson & Johnson Stock: Resilient Performance Amid Market Volatility

Healthcare giant Johnson & Johnson is demonstrating remarkable resilience in a volatile market environment. Currently trading at $165.68, the stock has established itself as a defensive asset

Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise
Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise

Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination

Johnson & Johnson Stock: Debt Concerns Rise After Strategic Acquisitions
Johnson & Johnson Stock: Debt Concerns Rise After Strategic Acquisitions

Johnson & Johnson's financial stability faces new scrutiny as S&P Global Ratings places the healthcare giant's newly issued senior unsecured bonds under negative watch, despite maintaining their